Orthopedics Medical News about Teriparatide, Glucocorticoid-induced osteoporosis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Teriparatide superior to alendronate for glucocorticoid-induced osteoporosis
American Pharmacists Association, 07/13/09

Pucino F – Study reports that teriparatide (a recombinant human parathyroid hormone) is more effective in increasing lumbar spine bone mineral density than alendronate (Fosamax—Merck) for patients suffering from glucocorticoid (GC)-induced osteoporosis.

Methods

Multicenter, randomized, trial evaluates the efficacy and safety of teriparatide vs alendronate in pts with GC-induced osteoporosis
427 ambulatory pts (≥21 yrs): 277 postmenopausal women, 67 premenopausal women, and 83 men
Before screening, all pts had received 5 mg/d or more of prednisone for 3 or more mo
Pts were randomized to receive:
- Teriparatide (n=213)- 20 mcg/d S.C. plus placebo tablets administered orally
- Alendronate (n=214)- 10 mg/d orally plus placebo sc
In addition, all pts received supplemental calcium (1,000 mg/d) and vit D (800 IU/d)
Primary outcome: changes in lumbar spine BMD
Secondary outcome: changes in hip BMD, bone biomarkers, the incidence of fractures, and safety

Results

Results from the 18-month primary phase of this 36-mo study:
- Mean % increases from baseline in lumbar spine BMD were greater for the teriparatide groups
- Radiographic vertebral fractures occurred in 1 patient randomized to teriparatide and 10 pts randomized to alendronate
- Nonvertebral fractures occurred in 12 pts randomized to teriparatide and 8 pts randomized to alendronate
- Prportion of pts reporting serious AEs was comparable between the 2 treatment groups
- However, nausea was reported by more pts receiving teriparatide

<< Previous
A Soccer-Specific Balance Training Program for Hamstring Muscle...

Next >>
Locking Plates for Extremity Fractures

Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis
Journal of Rheumatology, 11/19/09 Relevance Score: 80%

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial
Arthritis & Rheumatism, 11/03/09 Relevance Score: 80%

Teriparatide Outperforms Alendronate In Treating Steroid-induced Osteoporosis
ScienceDaily, 10/30/09 Relevance Score: 68%

Combination of Two Medications Help Postmenopausal Women with Osteoporosis
MedLinePlus, 10/30/09 Relevance Score: 67%

Teriparatide is safe and effectively increases bone biomarkers in institutionalized individuals with osteoporosis
Journal of Bone and Mineral Metabolism, 10/13/09 Relevance Score: 66%